Bevacizumab in ovarian cancer: Clinical data and predictive and prognostic biomarkers

Abstract

Angiogenesis, driven by the vascular endothelial growth factor (VEGF)/VEGFR signalling axis under hypoxic conditions, is one of the hallmarks of ovarian cancer (OC), contributing to tumour progression, metastatic dissemination and immune evasion. Hypoxia-induced angiogenic signalling sustains tumour growth and shapes an immunosuppressive tumour microenvironment, while homologous recombination deficiency (HRD) has been associated with increased tumour hypoxia and pro-angiogenic signalling. Conversely, VEGF pathway inhibition may exacerbate DNA damage and modulate immune cell trafficking, providing a strong biological rationale for synergy between anti-angiogenic agents, PARP inhibitors (PARPi), and immune checkpoint inhibitors. Bevacizumab, a humanised monoclonal antibody targeting VEGF-A, represents a pivotal therapeutic agent in OC management by inhibiting tumour angiogenesis and inducing transient vascular normalisation. Its clinical efficacy has been demonstrated as maintenance therapy in the first-line setting, alone or in combination with PARPi for HRD-positive disease, and in the recurrent setting both in platinum-sensitive and platinum-resistant disease. Despite these benefits, variability in patient response highlights the unmet need for validated predictive biomarkers. Circulating, tissue-based and molecular biomarkers have been investigated, including angiogenic factors (Tie2/Ang1 axis, interleukin-6 [IL-6] and chitinase-3-like protein [YKL-40]), VEGF-A isoforms, microvessel density, EGFR/ADAM17 signalling, angiomiRs and transcriptional subtypes with mesenchymal and proliferative phenotypes showing greater sensitivity to anti-angiogenic strategies. Although HRD status holds prognostic relevance and selected microRNAs show emerging potential, no biomarker has yet been validated to predict benefit from bevacizumab in clinical practice. Translational analyses from the MITO16A/MaNGO OV-2 program, highlight challenges such as assay standardisation, multiplicity correction and external validation, while identifying tumour immune infiltration patterns, TP53 mutation classes and composite HRD assessments as areas of further investigation. In conclusion, bevacizumab remains an integral component of OC treatment. Future progress will depend on biomarker-driven, prospectively designed clinical trials and the integration of multi-omic data and machine learning approaches to enable precision application of anti-angiogenic strategies, maximising clinical benefit while minimising toxicity.

Keywords

angiogenesis / bevacizumab / homologous recombination deficiency (HRD) / ovarian cancer / PARP inhibitors / predictive biomarkers / prognostic biomarkers / VEGF

References

[1] Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024; 21(5): 389-400.

[2] Barili V, Ambrosini E, Bortesi B, et al. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes. 2024; 15(2): 219.

[3] Caruso G, Weroha SJ, Cliby W. Ovarian cancer: a review. JAMA. 2025; 334(14): 1278-1291.

[4] Hablase R, Kyrou I, Randeva H, Karteris E, Chatterjee J. The “road” to malignant transformation from endometriosis to endometriosis-associated ovarian cancers (EAOCs): an mTOR-centred review. Cancers. 2024; 16(11): 2160.

[5] Daly MB, Dresher CW, Yates MS, et al. Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila Pa). 2015; 8(5): 342-348.

[6] Smolarz B, Biernacka K, Łukasiewicz H, et al. Ovarian cancer—epidemiology, classification, pathogenesis, treatment, and estrogen receptors’ molecular backgrounds. Int J Mol Sci. 2025; 26(10): 4611.

[7] Hong K, Geschwind JFH. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol. 2010; 37(2): 110-117.

[8] Wang Y, Zhu N, Liu J, et al. Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements. J Transl Med. 2025; 23(1): 539.

[9] Nan W, He Y, Wang S, Zhang Y. Molecular mechanism of VE-cadherin in regulating endothelial cell behaviour during angiogenesis. Front Physiol. 2023; 14:1234104.

[10] Magar AG, Morya VK, Kwak MK, Oh JU, Noh KC. A molecular perspective on HIF-1α and angiogenic stimulator networks and their role in solid tumors: an update. Int J Mol Sci. 2024; 25(6): 3313.

[11] Tang N, Wang L, Esko J, et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell. 2004; 6(5): 485-495.

[12] Garlisi B, Lauks S, Aitken C, et al. The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities. Curr Oncol. 2024; 31(7): 3826-3844.

[13] Gonzalez-Avila G, Sommer B, Flores-Soto E, Aquino-Galvez A. Hypoxic effects on matrix metalloproteinases’ expression in the tumor microenvironment and therapeutic perspectives. Int J Mol Sci. 2023; 24(23):16887.

[14] Lee JM, Brady MF, Miller A, et al. Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005. J Clin Oncol. 2024; 42(36): 4305-4316.

[15] Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009; 27(7): 1069-1074.

[16] Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020; 86:102017.

[17] Montemagno C, Pagès G. Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs. Front Cell Dev Biol. 2020; 8: 584.

[18] Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365(26): 2473-2483.

[19] Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26): 2484-2496.

[20] Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019; 381(25): 2416-2428.

[21] Musacchio L, Salutari V, Pignata S, et al. TP033/#1441 MITO 25.1: a randomized, molecular driven phase II trial of carboplatin‒paclitaxel‒bevacizumab vs carboplatin‒paclitaxel‒bevacizumab‒rucaparib vs carboplatin‒paclitaxel‒rucaparib, selected according to HRD status, in patients with advanced ovarian cancer. E-Posters (Trials In Progress). BMJ Publishing Group Ltd.; 2022:A239.2.

[22] Moore KN, Bookman M, Sehouli J, et al. Bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021; 39(17): 1842-1855.

[23] Harter P, Wimberger P, Okamoto A, et al. Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: updated results from DUO-O/ENGOT-OV46/GOG-3025 trial. Gynecol Oncol. 2024; 190: S65-S66.

[24] Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015; 139(1): 10-16.

[25] Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 2020; 21(5): 699-709.

[26] Taliento C, Morciano G, Nero C, et al. Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2024; 34(6): 906-918.

[27] Secord AA, Lewin S, Murphy C, et al. 76MO Final analysis of the single-arm phase II PICCOLO trial of mirvetuximab soravtansine-gynx (MIRV) in folate receptor alpha (FRα)-positive, third-line and later (3L+), recurrent platinum-sensitive ovarian cancer (PSOC). ESMO Open. 2025; 10:105205.

[28] Nerone M, Del Grande M, Colombo I. Antibody‒drug conjugates in ovarian cancer: promises and challenges. Healthbook TIMES Oncol Hematol. 2023;17:32-36.

[29] O'Malley DM, Myers TKN, Zamagni C, Diver E, Lorusso D. GLORIOSA: a randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol. 2023; 41(16_suppl): TPS5622-TPS5622.

[30] Kurtz JE, Pujade-Lauraine E, Oaknin A, et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE/ENGOT-ov29 trial. J Clin Oncol. 2023; 41(30): 4768-4778.

[31] Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014; 32(13): 1302-1308.

[32] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706): 58-62.

[33] Gilbert L, Oaknin A, Matulonis UA, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody‒drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023; 170: 241-247.

[34] Naumann RW, Lee JY, Herzog T, et al. REFRaME-O1/ENGOT-OV79/GOG-3086: a phase II/III, open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator's choice of chemotherapy in women with relapsed platinum-resistant epithelial ovarian cancer expressing folate receptor alpha. Gynecol Oncol. 2024; 190: S302.

[35] González-Martín A, Janco JMT, Lee JY, et al. 127TiP An open-label, randomized, multicenter, phase III study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line (1L) maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO 01). ESMO Open. 2025; 10:105253.

[36] Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019; 18(1): 60.

[37] Colombo N, Coleman RL, Wu X, et al. ENGOT-ov65/KEYNOTE-B96: phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2022; 40(16_suppl): TPS5617-TPS5617.

[38] Lacin S, Yalcin S. The prognostic value of circulating VEGF-A level in patients with hepatocellular cancer. Technol Cancer Res Treat. 2020; 19:1533033820971677.

[39] Komatsu H, Oishi T, Itamochi H, et al. Serum vascular endothelial growth factor-A as a prognostic biomarker for epithelial ovarian cancer. Int J Gynecol Cancer. 2017; 27(7): 1325-1332.

[40] Mohammed RAA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors-A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer. 2007; 96(7): 1092-1100.

[41] Werther K, Christensen IJ, Nielsen HJ, Danish RANX05 Colorectal Cancer Study Group. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer. 2002; 86(3): 417-423.

[42] Wang L, Chang Y, Xu J, Zhang Q. Predictive significance of serum level of vascular endothelial growth factor in gastric cancer patients. BioMed Res Int. 2016; 2016:8103019.

[43] Hegde PS, Jubb AM, Chen D, et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res. 2013; 19(4): 929-937.

[44] Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2006; 24(2): 217-227.

[45] Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012; 30(17): 2119-2127.

[46] Mok T, Gorbunova V, Juhasz E, et al. A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015). J Thorac Oncol. 2014; 9(6): 848-855.

[47] Hayashi H, Arao T, Matsumoto K, et al. Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget. 2014; 5(9): 2588-2595.

[48] Bates DO, Catalano PJ, Symonds KE, et al. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res. 2012; 18(22): 6384-6391.

[49] Pentheroudakis G, Mavroeidis L, Papadopoulou K, et al. Angiogenic and antiangiogenic VEGFA splice variants in colorectal cancer: prospective retrospective cohort study in patients treated with irinotecan-based chemotherapy and bevacizumab. Clin Colorectal Cancer. 2019; 18(4): e370-e384.

[50] Tanaka K, Sugisaka J, Shiraishi Y, et al. Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC. Nat Commun. 2025; 16(1): 2825.

[51] Formica V, Palmirotta R, Del Monte G, et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis. 2011; 26(2): 143-151.

[52] Loupakis F, Cremolini C, Yang D, et al. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PloS ONE. 2013; 8(7):e66774.

[53] Jubb AM, Miller KD, Rugo HS, et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011; 17(2): 372-381.

[54] Zuurbier L, Rahman A, Cordes M, et al. Apelin: a putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget. 2017; 8(26): 42949-42961.

[55] Nixon AB, Sibley AB, Liu Y, et al. Plasma protein biomarkers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: results from CALGB 80405 (Alliance). Clin Cancer Res. 2022; 28(13): 2779-2788.

[56] Bai L, Wang F, Zhang DS, et al. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer. Sci Rep. 2015; 5:17717.

[57] Abajo A, Boni V, Lopez I, et al. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer. 2012; 107(2): 287-290.

[58] Schuster C, Akslen LA, Stokowy T, Straume O. Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy. J Pathol Clin Res. 2019; 5(1): 53-62.

[59] Iorio J, Lastraioli E, Tofani L, et al. hERG1 and HIF-2α behave as biomarkers of positive response to bevacizumab in metastatic colorectal cancer patients. Transl Oncol. 2020; 13(3):100740.

[60] Muto S, Takagi H, Owada Y, et al. Serum nitric oxide as a predictive biomarker for bevacizumab in non-small cell lung cancer patients. Anticancer Res. 2017; 37(6): 3169-3174.

[61] Daniele G, Raspagliesi F, Scambia G, et al. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. Int J Gynecol Cancer. 2021; 31(6): 875-882.

[62] Collinson F, Hutchinson M, Craven RA, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res. 2013; 19(18): 5227-5239.

[63] Backen A, Renehan AG, Clamp AR, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res. 2014; 20(17): 4549-4558.

[64] Zhou C, Clamp A, Backen A, et al. Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab. Br J Cancer. 2016; 115(2): 228-235.

[65] Jayson GC, Zhou C, Backen A, et al. Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nat Commun. 2018; 9(1): 4672.

[66] Carucci M, Clamp A, Zhou C, et al. The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors. BMC Cancer. 2024; 24(1): 1309.

[67] Ding Y, Oliveira-Ferrer L, Vettorazzi E, et al. VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients. PloS ONE. 2022; 17(6):e0269680.

[68] Secord AA, Burdett KB, Owzar K, et al. Predictive blood-based biomarkers in patients with epithelial ovarian cancer treated with carboplatin and paclitaxel with or without bevacizumab: results from GOG-0218. Clin Cancer Res. 2020; 26(6): 1288-1296.

[69] Amer H, Flanagan KL, Kampan NC, et al. Interleukin-6 is a crucial factor in shaping the inflammatory tumor microenvironment in ovarian cancer and determining its hot or cold nature with diagnostic and prognostic utilities. Cancers. 2025; 17(10): 1691.

[70] Høgdall EVS, Johansen JS, Kjaer SK, et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep. 2003; 10(5): 1535-1538.

[71] Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004; 22(16): 3330-3339.

[72] Boisen MK, Madsen CV, Dehlendorff C, Jakobsen A, Johansen JS, Steffensen KD. The prognostic value of plasma YKL-40 in patients with chemotherapy-resistant ovarian cancer treated with bevacizumab. Int J Gynecol Cancer. 2016; 26(8): 1390-1398.

[73] Herzog B, Pellet-Many C, Britton G, Hartzoulakis B, Zachary IC. VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. Mol Biol Cell. 2011; 22(15): 2766-2776.

[74] Bais C, Mueller B, Brady MF, et al. Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst. 2017; 109(11):djx066.

[75] Klotz DM, Kuhlmann JD, Link T, et al. Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis. Front Oncol. 2022; 12:974885.

[76] Mutlu M, Raza U, Saatci Ö, Eyüpoğlu E, Yurdusev E, Şahin Ö. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance. J Mol Med Berl Ger. 2016; 94(6): 629-644.

[77] Halvorsen AR, Kristensen G, Embleton A, et al. Evaluation of prognostic and predictive significance of circulating microRNAs in ovarian cancer patients. Dis Markers. 2017; 2017:3098542.

[78] Werner B, Sjoquist KM, Espinoza D, et al. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial. Transl Oncol. 2024; 43:101914.

[79] Wimberger P, Gerber MJ, Pfisterer J, et al. Bevacizumab may differentially improve prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an antiangiogenic VEGF-A splice variant. Clin Cancer Res. 2022; 28(21): 4660-4668.

[80] Morgan RD, Ferreras C, Peset I, et al. c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trial. BMC Med. 2022; 20(1): 59.

[81] Volk A, Legler K, Hamester F, et al. Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer. J Cancer Res Clin Oncol. 2023; 149(17): 15957-15967.

[82] Avril S, Dincer Y, Malinowsky K, et al. Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. Oncotarget. 2017; 8(58): 97851-97861.

[83] Volk A, von Bülow C, Stern A, et al. Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?. J Cancer Res Clin Oncol. 2025; 151(2): 44.

[84] Chan JK, Kiet TK, Blansit K, et al. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. Gynecol Oncol. 2014; 133(3): 568-574.

[85] Wu B, Zhang L, Yu Y, et al. miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis. Cell Death Dis. 2020; 11(5): 345.

[86] He MY, Halford MM, Liu R, et al. Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. Commun Biol. 2021; 4(1): 878.

[87] Megiorni F, Camero S, Pontecorvi P, et al. OTX015 epi-drug exerts antitumor effects in ovarian cancer cells by blocking GNL3-mediated radioresistance mechanisms: cellular, molecular and computational evidence. Cancers. 2021; 13(7): 1519.

[88] Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008; 14(16): 5198-5208.

[89] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353): 609-615.

[90] Heublein S, Pfisterer J, du Bois A, et al. Fibroblast growth factor receptors and ligands in context of bevacizumab response in ovarian carcinoma: an exploratory analysis of AGO-OVAR11/ICON-7. Lab Investig J Tech Methods Pathol. 2024; 104(4):100321.

[91] Gao J, Li F, Liu Z, et al. Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: a retrospective study. Medicine (Baltimore). 2021; 100(35):e27130.

[92] Califano D, Gallo D, Vinciguerra GLR, et al. Evaluation of angiogenesis-related genes as prognostic biomarkers of bevacizumab treated ovarian cancer patients: results from the phase IV MITO16A/ManGO OV-2 translational study. Cancers. 2021; 13(20): 5152.

[93] Vecchione A, Belletti B, Lovat F, et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A. 2013; 110(24): 9845-9850.

[94] Rossello A, Nuti E, Ferrini S, Fabbi M. Targeting ADAM17 sheddase activity in cancer. Curr Drug Targets. 2016; 17(16): 1908-1927.

[95] Fabbi M, Costa D, Russo D, et al. Analysis of a disintegrin and metalloprotease 17 (ADAM17) expression as a prognostic marker in ovarian cancer patients undergoing first-line treatment plus bevacizumab. Diagn Basel Switz. 2022; 12(9): 2118.

[96] Forlani L, De Cecco L, Simeon V, et al. Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial. J Exp Clin Cancer Res CR. 2023; 42(1): 83.

[97] Bignotti E, Simeon V, Ardighieri L, et al. TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results of the MITO16A/MaNGO OV-2 study. Int J Cancer. 2025; 156(5): 1085-1096.

[98] Capoluongo ED, Pellegrino B, Arenare L, et al. Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial. ESMO Open. 2022; 7(5):100585.

[99] Roma C, Abate RE, Sacco A, et al. Harmonization of homologous recombination deficiency testing in ovarian cancer: results from the MITO16A/MaNGO-OV2 trial. Eur J Cancer. 2024; 206:114127.

[100] Pellegrino B, Capoluongo ED, Bagnoli M, et al. Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial. ESMO Open. 2025; 10(1):104091.

[101] Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, et al. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation. EMBO Mol Med. 2018; 10(12):e9172.

[102] Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer. 2022; 22(11): 640-656.

[103] Mezzapelle R, Leo M, Caprioglio F, et al. CXCR4/CXCL12 activities in the tumor microenvironment and implications for tumor immunotherapy. Cancers. 2022; 14(9): 2314.

[104] D'Alterio C, Spina A, Arenare L, et al. Biological role of tumor/stromal CXCR4‒CXCL12‒CXCR7 in MITO16A/MaNGO-OV2 advanced ovarian cancer patients. Cancers. 2022; 14(7): 1849.

[105] Basso-Valentina F, Canzonieri V, De Cecio R, et al. Programmed death-ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: results from the phase IV MITO16A/MaNGO OV-2 translational study. Clin Transl Med. 2025; 15(6):e70373.

[106] Pivetta E, Canzonieri V, Bagnoli M, et al. Tumour-infiltrating leucocytes as prognostic biomarkers of bevacizumab-treated ovarian cancer patients results from the phase IV MITO16A/MaNGO OV-2 clinical trial. NPJ Precis Oncol. 2025; 9(1): 355.

[107] Zeng Q, Klein C, Caruso S, et al. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study. Lancet Oncol. 2023; 24(12): 1411-1422.

[108] Polano M, Bedon L, Dal Bo M, et al. Machine learning application identifies germline markers of hypertension in patients with ovarian cancer treated with carboplatin, taxane, and bevacizumab. Clin Pharmacol Ther. 2023; 114(3): 652-663.

[109] Maiorano MFP, Cormio G, Loizzi V, Maiorano BA. Artificial intelligence in ovarian cancer: a systematic review and meta-analysis of predictive AI models in genomics, radiomics, and immunotherapy. AI. 2025; 6(4): 84.

[110] Restaino S, De Giorgio MR, Pellecchia G, et al. Artificial intelligence in gynecological oncology from diagnosis to surgery. Cancers. 2025; 17(7): 1060.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.